514 related articles for article (PubMed ID: 29616439)
21. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
[TBL] [Abstract][Full Text] [Related]
22. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
[TBL] [Abstract][Full Text] [Related]
23. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
25. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
26. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract][Full Text] [Related]
28. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
29. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
McAndrew EN; Zhang H; Lambert P; Rittberg R; Dawe DE; Kim CA
Am J Clin Oncol; 2022 Feb; 45(2):55-60. PubMed ID: 35073280
[TBL] [Abstract][Full Text] [Related]
30. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Nichetti F; Rota S; Ambrosini P; Pircher C; Gusmaroli E; Droz Dit Busset M; Pusceddu S; Sposito C; Coppa J; Morano F; Pietrantonio F; Di Bartolomeo M; Mariani L; Mazzaferro V; de Braud F; Niger M
JAMA Netw Open; 2024 Jan; 7(1):e2350756. PubMed ID: 38190183
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Taguchi H; Otsuka T; Shimokawa M; Arima S; Hashimoto S; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Honda T; Shibuki T; Mizuta T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T
Anticancer Res; 2021 Jul; 41(7):3573-3582. PubMed ID: 34230153
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
[TBL] [Abstract][Full Text] [Related]
34. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
35. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H
Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL
Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750
[TBL] [Abstract][Full Text] [Related]
39. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
40. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]